|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Contribution of functional KIR3DL1 to ankylosing spondylitis显示文摘Increasing evidence points to a role for killer immunoglobulin-like receptors(KIRs)in the development of autoimmune diseases.In particular,a positive association of KIR3DS1(activating receptor)and a negative association of KIR3DL1(inhibitory receptor)alleles with ankylosing spondylitis(AS)have been reported by several groups.However,none of the studies analyzed these associations in the context of functionality of polymorphic KIR3DL1.To better understand how the KIR3DL1/3DS1 genes determine susceptibility to AS,we analyzed the frequencies of alleles and genotypes encoding functional(KIR3DL1*F)and non-functional(KIR3DL1*004)receptors.We genotyped 83 AS patients and 107 human leukocyte antigen(HLA)-B27-positive healthy controls from the Russian Caucasian population using a two-stage sequence-specific primer PCR,which distinguishes KIR3DS1,KIR3DL1*F and KIR3DL1*004 alleles.For the patients carrying two functional KIR3DL1 alleles,those alleles were additionally genotyped to identify KIR3DL1*005 and KIR3DL1*007 alleles,which are functional but are expressed at low levels.KIR3DL1 was negatively associated with AS at the expense of KIR3DL1*F but not of KIR3DL1*004.This finding indicates that the inhibitory KIR3DL1 receptor protects against the development of AS and is not simply a passive counterpart of the segregating KIR3DS1 allele encoding the activating receptor.However,analysis of genotype frequencies indicates that the presence of KIR3DS1 is a more important factor for AS susceptibility than the absence of KIR3DL1*F.The activation of either natural killer(NK)or T cells via the KIR3DS1 receptor can be one of the critical events in AS development,while the presence of the functional KIR3DL1 receptor has a protective effect.Nevertheless,even individuals with a genotype that carried two inhibitory KIR3DL1 alleles expressed at high levels could develop AS. | Ivan V Zvyagin Ilgar Z Mamedov Olga V Britanova Dmitriy B Staroverov Evgeni L Nasonov Anna G Bochkova Anna V Chkalina Alexei A Kotlobay Dmitriy O Korostin Denis V Rebrikov Sergey Lukyanov Yuri B Lebedev Dmitriy M Chudakov | 2010 | Cellular & Molecular Immunology2010，7，6： | 5 |
| 2 | Interleukin-6 re- ceptor inhibition with tocilizumab reduces disease activity in rheu- matoid arthritis with inadequate response to disease-modifying an- tirheumatic drugs: the tocilizumab in combination with traditional disease-modifying anfirheumatic drug therapy study 显示文摘 | Genovese MC McKay JD Nasonov EL | 2008 | Arthritis Rheum2008，58，10： | 1 |
| 3 | Bone mineral density in patients with rheumatoid arthritis 显示文摘 | Gukasian DA Nasonov EL Balabanova RM | 2001 | Ter Arkh2001，73，： | 1 |
| 4 | Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs:the tocilizumab in combination with traditional disease-modifying antirhe-umatic drug therapy study显示文摘 | Genovese M C McKay J D Nasonov EL | 2008 | Arthritis Rheum2008，58，10： | 1 |
| 5 | Soluble adhesion molecules (P-selectin,ICAM-1 and ICAM-3) in rheumatoid arthritis显示文摘 | SAMSONOV MIU TILZ GP | 1999 | Abstract Ter Arkh1999，71，5： | 1 |
| 6 | lntedeu- kin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modif- ying antirheumatic drugs: The toeilizumab in combination with traditional disease-modifying antirheumatic drug therapy study 显示文摘 | GENOVESE MC MCKAY JD NASONOV EL | 2008 | Arthritis Rheum2008，58，10： | 1 |
| 7 | Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate re- sponse to disease-modifying antirheumatic drugs: The to- cilizumab in combination with traditional disease-modif- ying antirheumatic drug therapy study 显示文摘 | GENOVESE M C MCKAY J D NASONOV E L | 2008 | Arthritis and Rheumatism2008，58，10： | 1 |
| 8 | The role of regulatory T-cells in au toimmune rheumatic diseases显示文摘 | Nasonov E L Bykovskaia S N | 2006 | Vestn Ross Akad Med Nauk2006，9，10： | 1 |
| 9 | Sys- temic autoimmune rheumatic diseases in 2013:Problems of laboratory diagnosis显示文摘 | Nasonov EL Aleksandrova EN Novikov AA | 2014 | Ter Arkh2014，86，5： | 1 |
| 10 | Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs:the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study显示文摘 | Genovese MC McKay JD Nasonov EL | 2008 | Arthritis Rheum2008，58，10： | 1 |
| 11 | Hemorheological and clinical efficiency of a new phospholipid hepatoprotective drug Phosphogliv in patients with psoriatic arthritis显示文摘 | Nasonov EL Korotaeva TV | 2003 | Biomed Khim2003，49，5： | 1 |
| 12 | Cardiac rhythm and conduction disorders in polymyositis and dermatomyositis显示文摘 | Bazhanov NN Khitrov AN Nasonov EL | 1998 | Kiln Med (Mosk)1998，76，10： | 1 |
| 13 | Interleukin-6receptor inhibition with tocilizumab reduces disease activity inrheumatoid arthritis with inadequate response to disease-modify-ing antirheumatic drugs: the tocilizumab in combination withtraditional disease-modifying antirheumatic drug therapy study 显示文摘 | Genovese MC McKay JD Nasonov EL | 2008 | Arthritis Rheum2008，58，10： | 1 |
| 14 | Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients:results of a 1-year follow-up study from the CERERRA collaboration显示文摘 | Chatzidionysiou K Lie E Nasonov E | 2012 | Ann Rheum dis2012，71，3： | 1 |
| 15 | Insulin resistance syndrome in patients with gout and its influence on formation of clinical characteristics of the disease显示文摘 | Barskova VG Eliseev MS Nasonov EL | 2004 | Ter Arkh2004，76，5： | 1 |
| 16 | The role of regulatory T-cells in autoimmune rheumatic diseases显示文摘 | Nasonov EL Bykovskaia SN | 2006 | Vestn RossAkad Med Nauk2006，，910： | 1 |
| 17 | Interleukin- 6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study 显示文摘 | Genovese M C McKay J D Nasonov E L | 2008 | Arthritis Rheum2008，58，29： | 1 |
| 18 | Serum neopterin in hepatitis B显示文摘 | Samsonov M Golban TD Nasonov EL | 1992 | Klin Med (Mosk)1992，70，： | 1 |
| 19 | The effi- ciency and safety of adalimumah treatment in patients with active rheumatoid arthritis unresponsive to standard therapy: Russian national study results显示文摘 | Karateev D E Nasonov E L Luchikhina E L | 2012 | Ter Arkh2012，84，8： | 1 |
| 20 | Insulin resistance syndrome in patients with gout and its influence on formation of clinical characteristics of the disease 显示文摘 | Barskova VG Eliseev MS Nasonov EL | 2004 | Ter Arkh2004，76，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员